

# The 2nd International Workshop on Radiobiology of Molecular Radionuclide Therapy (IWRMR)

**13<sup>th</sup> - 14<sup>th</sup> March 2023**

Francis Crick Institute, London UK

## Day 1 – Monday 13<sup>th</sup> March 2023

9.00 - 10.00	Registration with tea and coffee
10.00 - 10.10	Welcome <i>Samantha Terry, King's College London, UK</i>
10.10 - 11.10	<b>Keynote 1:</b> State-of-the-art MRT and where efforts best laid for impactful clinical success <i>Jonathan Wadsley, University of Sheffield, UK</i>
11.10 - 12.10	Promising efficacy of CAIX-targeted lutetium-177 radionuclide therapy combined with immune checkpoint inhibition <i>Simone Kleinendorst, Radboud University Medical Centre, Netherlands</i>  p53 stabilization potentiates <sup>177</sup> Lu-DOTATATE treatment in neuroblastoma <i>Hanna Berglund, Uppsala University, Sweden</i>  Prostate cancer xenografts treatment with CD46 targeted, <sup>225</sup> Ac -abelled antibody <i>Anil Bidkar, University of California, USA</i>
12.10 - 13.15	Lunch
13.15 - 14.15	MRT and vesicle signaling <i>Julie Constanzo, Montpellier Cancer Research Institute IRCM, France</i>
14.15 - 15.15	Characterization and role of dsDNA contained in extracellular vesicles released by irradiated cells <i>Yasmine Bouden, Université de Montpellier, France</i>  The anti-tumour immune response induced by [ <sup>177</sup> Lu]Lu-PSMA <i>Gemma Dias, University of Oxford, UK</i>  Molecular targeted radiotherapy induces a systemic immune response in men with prostate cancer <i>Sapna Lunj, The University of Manchester, UK</i>
15.15 - 15.45	Poster Pitches
15.45 - 16.30	Tea and Coffee Break with Poster session 1
16.30 - 17.30	Networking session
17.30 - 19.30	Drinks Reception

## Day 2 – Tuesday 14<sup>th</sup> March 2023

9.00 – 9.30	Tea & Coffee
9.30 – 10.00	Targeting hypoxic WSB-1 biology as a radiosensitising approach in breast cancer <i>Isabel Pires, University of Hull, UK</i>
10.00 – 11.00	Audience-engaged discussion
11.00 - 11.20	Tea & Coffee Break
11.20 - 12.20	<b>Keynote 2:</b> How the tumour microenvironment might influence MRT success <i>Fran Balkwill, Queen Mary University of London, UK</i>
12.20 - 12.30	Industry talk <i>Marco Ranzani, Artios, UK</i>
12.30 - 13.45	Lunch and Poster session 2
13.45 - 14.45	Cellular studies of <sup>67</sup> Ga/ <sup>177</sup> Lu-labeled nanoparticles for the theranostics of glioblastoma <i>Paula Raposinho, Technical University of Lisbon, Portugal</i>
	Challenges in radiation biology: from the radiation' nano-scopic pattern to biological effectiveness <i>Ana belchior, Technical University of Lisbon, Portugal</i>
	Absorbed dose-effect relationship in tumours and healthy organs for patients treated with <sup>177</sup> Lu-DOTATATE <i>Emmanuel Deshayes, Montpellier Cancer Research Institute IRCM , France</i>
14.45 - 15.30	Tea & Coffee break with Networking
15.30 - 16.10	Clonogenic-based drug screens for lutetium-based combination therapy <i>Edward O'Neill, University of Oxford, UK</i>
	High-throughput screens identify DNA-PKcs inhibitors as radiosensitizers for peptide receptor radionuclide therapy <i>in vitro</i> and <i>in vivo</i> <i>Thom Reuvers, Erasmus University Medical Centre, Netherlands</i>
16.10 - 16.30	Closing statements <i>Samantha Terry, King's College London, UK</i>

**Sponsors.** Thank you to Viewpoint Molecular Targeting for sponsoring our lunches for this workshop and MILabs for sponsoring our drinks reception.

